XLV — State Street Health Care Select Sector SPDR ETF
Healthcare Ranked #50 of 458 tracked ETFs · Issued by State Street Investment Management
XLV Price Performance — Growth of $10,000
Value of a $10,000 investment in XLV over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
XLV Drawdown
The "underwater" chart: XLV's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in XLV?
See what a lump sum in XLV would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The State Street Health Care Select Sector SPDR ETF (XLV) is a healthcare-focused exchange-traded fund, issued by State Street Investment Management. With a current overall rank of #50 among 458 tracked ETFs, it is positioned in the middle of the pack. The ETF has an expense ratio of 0.08%, indicating a relatively low cost for investors, and a dividend yield of 1.05%, offering a modest income stream. The fund's price stands at $174.62, and it has an assets under management (AUM) of $41.7B, suggesting significant investor adoption and liquidity. This combination of a moderate price and substantial AUM implies that the ETF is well-liked by investors, likely due to its strong performance and low cost structure.
The performance of the State Street Health Care Select Sector SPDR ETF (XLV) has shown a steady upward trend over the past year, with returns accelerating over time. In the short term, the fund saw a 1-day return of +1.29%, indicating a relatively stable daily performance. Over the longer term, the 1-year return of +29.21% and the 3-year return of +37.32% demonstrate consistent growth. The 1-month return of +8.16% and the 3-month return of +18.39% suggest that the fund has been particularly strong in the recent past, with a noticeable acceleration in performance. This pattern indicates that the ETF has been performing well across various time horizons, with a notable improvement in returns over the last year.
The State Street Health Care Select Sector SPDR ETF (XLV) is labeled as having a moderate volatility, with a beta of 0.51, indicating that it is less volatile than the broader market. This suggests that the fund is likely to experience smaller price fluctuations compared to the S&P 500. The Sharpe ratio of 1.51 is relatively high, which means that the fund has provided a good risk-adjusted return, balancing its volatility with higher returns. The maximum drawdown of -17.11% indicates that the fund has experienced a significant decline in value, but it has recovered from this downturn. This combination of moderate volatility, a high Sharpe ratio, and a significant drawdown suggests that the fund is suitable for investors who are looking for a balance between risk and reward, with the potential for higher returns in a bull market, but with some downside risk in a bear market.
AI-generated summary based on the data on this page.
XLV Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | Eli Lilly & Co | 13.74% | $5.30B |
| 2 | Johnson & Johnson | 11.10% | $4.29B |
| 3 | AbbVie Inc | 7.25% | $2.80B |
| 4 | Merck & Co Inc | 5.63% | $2.17B |
| 5 | UnitedHealth Group Inc | 4.62% | $1.78B |
| 6 | Amgen Inc | 3.57% | $1.38B |
| 7 | Thermo Fisher Scientific Inc | 3.48% | $1.34B |
| 8 | Abbott Laboratories | 3.37% | $1.30B |
| 9 | Gilead Sciences Inc | 3.26% | $1.26B |
| 10 | Intuitive Surgical Inc | 3.09% | $1.19B |
Holdings as of 2026-03-31 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 59.1% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how XLV's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With XLV
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with XLV's top 10 — FHLC overlaps most, holding 10 of the same companies as XLV's top 10 (59.1% of XLV's assets).
| ETF | Name | Shared Companies | XLV Weight | Examples |
|---|---|---|---|---|
| FHLC | Fidelity MSCI Health Care Index ETF | 10 | 59.1% | Eli Lilly & Co, Johnson & Johnson, AbbVie Inc… |
| VHT | Vanguard Health Care Index Fund ETF Shares | 9 | 55.7% | Eli Lilly & Co, Johnson & Johnson, AbbVie Inc… |
| IYH | iShares U.S. Healthcare ETF | 9 | 45.4% | Johnson & Johnson, AbbVie Inc, UnitedHealth Group Inc… |
| PPH | VanEck Pharmaceutical ETF | 3 | 30.5% | Eli Lilly & Co, Johnson & Johnson, Merck & Co Inc |
| HDV | iShares Core High Dividend ETF | 3 | 24.0% | Johnson & Johnson, AbbVie Inc, Merck & Co Inc |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.69% (as of 2026-08-20) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 16.01 (as of 2026-08-20) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-07-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What XLV's Fees Cost You
XLV charges an expense ratio of 0.08% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
XLV Dividend Income Estimator
XLV currently yields 1.05%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
XLV Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is — and average daily volume is 10.5M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $41.7B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: XLV is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
XLV Performance History
| Period | Return |
|---|---|
| 1-Day | +1.29% |
| 1-Week | +4.33% |
| 1-Month | +8.16% |
| 3-Month | +18.39% |
| 6-Month | +12.30% |
| YTD | +13.25% |
| 1-Year | +29.21% |
| 3-Year | +37.32% |
How XLV Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #42 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +30.92% | 0.09% | $20.9B |
| #50 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +29.21% | 0.08% | $41.7B |
| #54 | B |
XBI | State Street SPDR S&P Biotech ETF | +86.60% | 0.35% | $9.63B |
| #76 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +31.01% | 0.084% | $3.29B |
| #87 | B |
IBB | iShares Biotechnology ETF | +54.68% | 0.44% | $9.21B |
| #130 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +58.31% | 0.35% | $489M |
| #161 | B |
IYH | iShares U.S. Healthcare ETF | +29.33% | 0.38% | $3.56B |
| #162 | B |
PPH | VanEck Pharmaceutical ETF | +34.20% | 0.36% | $926M |
| #236 | C |
ARKG | ARK Genomic Revolution ETF | +105.87% | 0.75% | $1.56B |
| #384 | C |
IHF | iShares U.S. Healthcare Providers ETF | +24.43% | 0.37% | $1.25B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -9.87% | 0.37% | $3.25B |